Clinical Focus
Business Focus
Spotlight
Subscribe
CE/CME
- CDC News
- Adult Immunization
- Hepatology
- Rare Disorders
- Pediatric Immunization
- Weight Management
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Kidney Disease
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Geriatrics
- Infectious Disease
- Orthopedics
- Obesity Medicine
- Rheumatology
- Technology
- Oncology
- Nephrology
- Neurology
- Pulmonology
ADA 2017: Insulins go Head-to-Head
Insulin degludec vs glargine--which costs less per anum and why? We summarize this study and 2 other direct insulin comparisons reported at ADA 2017.
Studies at the American Diabetes Association (ADA) 77th Scientific Sessions included direct comparisons of a variety of insulin formulations and regimens. Click through the slides above for summaries of 3 studies that evaluate basal insulins in elderly patients; examine the differences between an insulin/oral agent vs insulin only regimen; and report on a cost-benefit analysis of insulin glargine vs insulin degludec -- one costs less because it causes less hypoglycemia.
Related Videos
